Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026.